SHSicong Huang

Sicong Huang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sicong Huang has a total of 87 co-authors. Here are the top co-authors by number of shared publications:

  • Jeffrey Andrew Sparks

    Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital, Harvard Medical School, Boston, USA

    5 shared publications
  • Paul F. Dellaripa

    W. Huang, MSPH, P.F. Dellaripa, MD, S. Huang, MD, MS, V. Feathers, MS, B. Lu, MD, DrPH, M.E. Weinblatt, MD, N.A. Shadick, MD, MPH, J.A. Sparks, MD, MMSc, Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston

    4 shared publications
  • Allison A. Marshall

    Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, 60 Fenwood Road, Boston, MA 02115, United States; Tufts University School of Medicine, 145 Harrison Avenue, Boston, MA 02111, United States

    3 shared publications
  • Brittany Weber

    University of Texas Southwestern Medical Center

    3 shared publications
  • Katherine P. Liao

    Brigham and Women's Hospital Boston Massachusetts

    3 shared publications
  • Michael E. Weinblatt

    Division of Rheumatology, Inflammation, and Immunity Brigham and Women’s Hospital, Harvard Medical School Boston MA

    3 shared publications

Latest Publications

  • Open Access

    Interplay Between Systemic Inflammation, Myocardial Injury, and Coronary Microvascular Dysfunction in Rheumatoid Arthritis: Results From the LiiRA Study

    by Brittany Weber, Dana Weisenfeld, Elena Massarotti, Thany Seyok, Gabrielle Cremone, Ethan Lam, Charlotte Golnik, Seth Brownmiller, Feng Liu, Sicong Huang, et al.

    Background: Coronary microvascular dysfunction as measured by myocardial flow reserve (MFR) is associated with increased cardiovascular risk in rheumatoid arthritis (RA). The objective of this study was to determine the association between reducing inflammation with MFR and other measures of cardiovascular risk. Methods and Results: Patients with RA with active disease about to initiate a tumor necrosis factor inhibitor were enrolled (NCT02714881). All subjects underwent a cardiac perfusion positron emission tomography scan to quantify MFR at baseline before tumor necrosis factor inhibitor initiation, and after tumor necrosis factor inhibitor initiation at 24 weeks. MFR P =0.6) or hs‐cTnT. A correlation was observed between a reduction in hsCRP and interleukin‐1b with a reduction in hs‐cTnT. Conclusions: In this RA cohort with low prevalence of cardiovascular risk factors, nearly 50% of subjects had coronary microvascular dysfunction at baseline. A reduction in inflammation was not associated with improved MFR. However, a modest reduction in interleukin‐1b and no other inflammatory pathways was correlated with a reduction in subclinical myocardial injury. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02714881.


  • Association Between Inflammation, Incident Heart Failure, and Heart Failure Subtypes in Patients With Rheumatoid Arthritis

    by Sicong Huang, Tianrun Cai, Brittany N. Weber, Zeling He, Kumar P. Dahal, Chuan Hong, Jue Hou, Thany Seyok, Andrew Cagan, Marcelo F. DiCarli, et al.

    Objective: In rheumatoid arthritis (RA), there are limited data on risk factors for the clinical heart failure (HF) subtypes of HF with reduced ejection fraction (HFrEF) and HF with preserved ejection fraction (HFpEF). This study examined the association between inflammation and incident HF subtypes in RA. Because inflammation changes over time with disease activity, we hypothesized that the effect of inflammation may be stronger at the 5‐year follow‐up than at the standard 10‐year follow‐up from general population studies of cardiovascular risk.Methods: We studied an electronic health record (EHR)–based RA cohort with data pre‐ and post‐RA incidence. We applied a validated approach to identify HF and extract ejection fraction to classify HFrEF and HFpEF. Follow‐up started from the RA incidence date (index date) to the earliest occurrence of incident HF, death, last EHR encounter, or 10 years. Baseline inflammation was assessed using erythrocyte sedimentation rate or C‐reactive protein values. Covariates included demographic characteristics, established HF risk factors, and RA‐related factors. We tested the association between baseline inflammation with incident HF and its subtypes using Cox proportional hazards models.Results: We studied 9,087 patients with RA; 8.2% developed HF during 10 years of follow‐up. Elevated inflammation was associated with increased risk for HF at both 5‐ and 10‐year follow‐ups (hazard ratio [HR] 1.66, 95% confidence interval [95% CI] 1.12–2.46 and HR 1.46, 95% CI 1.13–1.90, respectively), which is also seen for HFpEF at 5 years (HR 1.72, 95% CI 1.09–2.70) and 10 years (HR 1.45, 95% CI 1.07–1.94). HFrEF was not associated with inflammation for either follow‐up time.Conclusion: Elevated inflammation early in RA diagnosis was associated with HF; this association was driven by HFpEF and not HFrEF, suggesting a window of opportunity for prevention of HFpEF in RA.


  • Open Access

    Relationship Between Risk of Atherosclerotic Cardiovascular Disease, Inflammation, and Coronary Microvascular Dysfunction in Rheumatoid Arthritis

    by Brittany Weber, Dana Weisenfeld, Thany Seyok, Sicong Huang, Elena Massarotti, Leanne Barrett, Courtney Bibbo, Daniel H. Solomon, Jorge Plutzky, Marcy Bolster, et al.


  • Semisupervised Calibration of Risk with Noisy Event Times (SCORNET) using electronic health record data

    by Yuri Ahuja, Liang Liang, Doudou Zhou, Sicong Huang, Tianxi Cai

    Summary: Leveraging large-scale electronic health record (EHR) data to estimate survival curves for clinical events can enable more powerful risk estimation and comparative effectiveness research. However, use of EHR data is hindered by a lack of direct event time observations. Occurrence times of relevant diagnostic codes or target disease mentions in clinical notes are at best a good approximation of the true disease onset time. On the other hand, extracting precise information on the exact event time requires laborious manual chart review and is sometimes altogether infeasible due to a lack of detailed documentation. Current status labels—binary indicators of phenotype status during follow-up—are significantly more efficient and feasible to compile, enabling more precise survival curve estimation given limited resources. Existing survival analysis methods using current status labels focus almost entirely on supervised estimation, and naive incorporation of unlabeled data into these methods may lead to biased estimates. In this article, we propose Semisupervised Calibration of Risk with Noisy Event Times (SCORNET), which yields a consistent and efficient survival function estimator by leveraging a small set of current status labels and a large set of informative features. In addition to providing theoretical justification of SCORNET, we demonstrate in both simulation and real-world EHR settings that SCORNET achieves efficiency akin to the parametric Weibull regression model, while also exhibiting semi-nonparametric flexibility and relatively low empirical bias in a variety of generative settings.


  • Relationship Between Rheumatoid Arthritis and Pulmonary Function Measures on Spirometry in the UK Biobank

    by Lauren Prisco, Matthew Moll, Jiaqi Wang, Brian D. Hobbs, Weixing Huang, Lily W. Martin, Vanessa L. Kronzer, Sicong Huang, Edwin K. Silverman, Tracy J. Doyle, et al.

    Objective: To investigate the independent relationship of rheumatoid arthritis (RA) to the type and severity of pulmonary patterns on spirometry compared to the pulmonary patterns in general population controls.Methods: In this cross‐sectional study, we investigated the association of RA with pulmonary function measures on spirometry among subjects in the UK Biobank who underwent spirometry for research purposes. RA cases were identified based on self‐report and current disease‐modifying antirheumatic drug/glucocorticoid use. Controls were subjects without RA from the general population. Outcome measures included continuous forced expiratory volume in 1 second percent predicted (FEV1%) and forced vital capacity percent predicted (FVC%), type of spirometric pattern (restrictive or obstructive), and severity of the restrictive or obstructive pattern. We used multivariable regression to estimate the effects in RA cases compared to the effects in controls, adjusting for age, sex, body mass index, and smoking status/pack‐years.Results: Among 350,776 analyzed subjects who underwent spirometry (mean age 56.3 years; 55.8% female; 45.5% ever smokers), we identified 2,008 cases of treated RA. In multivariable analyses, RA was associated with lower FEV1% (β = –2.93 [95% confidence interval (95% CI) –3.63, –2.24]), FVC% (β = –2.08 [95% CI –2.72, –1.45]), and FEV1/FVC (β = –0.008 [95% CI –0.010, –0.005]) compared to controls. RA was additionally associated with restrictive patterns (odds ratio [OR] 1.36 [95% CI 1.21, 1.52]) and obstructive patterns (OR 1.21 [95% CI 1.07, 1.37]) independent of confounders, and was most strongly associated with severe restrictive and obstructive patterns.Conclusion: RA is associated with increased odds of restrictive and obstructive patterns, and this relationship is not explained by confounders, including smoking status. In addition to restrictive lung disease, clinicians should also be aware that airway obstruction may be a pulmonary manifestation of RA.


  • Open Access

    Impact of ICD10 and secular changes on electronic medical record rheumatoid arthritis algorithms

    by Sicong Huang, Jie Huang, Tianrun Cai, Kumar P Dahal, Andrew Cagan, Zeling He, Jacklyn Stratton, Isaac Gorelik, Chuan Hong, Tianxi Cai, et al.

    Objective: The objective of this study was to compare the performance of an RA algorithm developed and trained in 2010 utilizing natural language processing and machine learning, using updated data containing ICD10, new RA treatments, and a new electronic medical records (EMR) system. Methods: We extracted data from subjects with ≥1 RA International Classification of Diseases (ICD) codes from the EMR of two large academic centres to create a data mart. Gold standard RA cases were identified from reviewing a random 200 subjects from the data mart, and a random 100 subjects who only have RA ICD10 codes. We compared the performance of the following algorithms using the original 2010 data with updated data: (i) a published 2010 RA algorithm; (ii) updated algorithm, incorporating ICD10 RA codes and new DMARDs; and (iii) published algorithm using ICD codes only, ICD RA code ≥3. Results: The gold standard RA cases had mean age 65.5 years, 78.7% female, 74.1% RF or antibodies to cyclic citrullinated peptide (anti-CCP) positive. The positive predictive value (PPV) for ≥3 RA ICD was 54%, compared with 56% in 2010. At a specificity of 95%, the PPV of the 2010 algorithm and the updated version were both 91%, compared with 94% (95% CI: 91, 96%) in 2010. In subjects with ICD10 data only, the PPV for the updated 2010 RA algorithm was 93%. Conclusion: The 2010 RA algorithm validated with the updated data with similar performance characteristics as the 2010 data. While the 2010 algorithm continued to perform better than the rule-based approach, the PPV of the latter also remained stable over time.


  • Lifestyle and Clinical Risk Factors for Incident Rheumatoid Arthritis-associated Interstitial Lung Disease

    by Vanessa L. Kronzer, Weixing Huang, Paul F. Dellaripa, Sicong Huang, Vivi Feathers, Bing Lu, Christine K. Iannaccone, Ritu R. Gill, Hiroto Hatabu, Mizuki Nishino, et al.

    Objective: To determine the association between novel lifestyle factors on risk of rheumatoid arthritis (RA)-associated interstitial lung disease (ILD), define the threshold at which smoking increases RA-ILD risk, and calculate the degree to which known lifestyle and clinical factors predict RA-ILD.Methods: This nested case-control study matched incident RA-ILD cases to RA non-ILD controls on age, sex, RA duration, rheumatoid factor, and time from exposure assessment to RA-ILD. Exposures included education, BMI, smoking, anticyclic citrullinated peptide antibodies, race, joint erosions, rheumatoid nodules, C-reactive protein (CRP), disease activity score, functional status, disease-modifying antirheumatic drug use, and glucocorticoid use. OR for each exposure on risk of RA-ILD were obtained from logistic regression models. Area under the curve (AUC) was calculated based on all lifestyle and clinical exposures.Results: We identified 84 incident RA-ILD cases and 233 matched controls. After adjustment, obesity, high-positive CRP (≥ 10 mg/L), and poor functional status (multidimensional Health Assessment Questionnaire [MDHAQ] ≥ 1) were associated with increased risk of RA-ILD (OR 2.42, 95% CI 1.11–5.24 vs normal BMI; OR 2.61, 95% CI 1.21–5.64 vs CRP < 3 mg/L; OR 3.10, 95% CI 1.32–7.26 vs MDHAQ < 0.2). Smoking 30 pack-years or more was strongly associated with risk of RA-ILD compared to never smokers (OR 6.06, 95% CI 2.72–13.5). Together, lifestyle and clinical risk factors for RA-ILD had an AUC of 0.79 (95% CI 0.73–0.85).Conclusion: Obesity, CRP, functional status, and extensive smoking may be novel risk factors for RA-ILD that may be useful for RA-ILD risk assessment and prevention. The overall ability to predict RA-ILD remains modest.


  • Rheumatoid arthritis-related lung disease detected on clinical chest computed tomography imaging: Prevalence, risk factors, and impact on mortality

    by Sicong Huang, Tracy J. Doyle, Mark M. Hammer, Suzanne C. Byrne, Weixing Huang, Allison A. Marshall, Christine K. Iannaccone, Jie Huang, Vivi Feathers, Michael E. Weinblatt, et al.


  • Correction to: Association of rheumatoid arthritis-related autoantibodies with pulmonary function test abnormalities in a rheumatoid arthritis registry

    by Sicong Huang, Xintong He, Tracy J. Doyle, Alessandra Zaccardelli, Allison A. Marshall, H. Maura Friedlander, Rachel B. Blaustein, Elisabeth A. Smith, Jing Cui, Christine K. Iannaccone, et al.

    The publisher regrets that the two sections under the Results omitted inadvertently on the original published version of the above article.

  • Association of rheumatoid arthritis-related autoantibodies with pulmonary function test abnormalities in a rheumatoid arthritis registry

    by Sicong Huang, Xintong He, Tracy J. Doyle, Alessandra Zaccardelli, Allison A. Marshall, H. Maura Friedlander, Rachel B. Blaustein, Elisabeth A. Smith, Jing Cui, Christine K. Iannaccone, et al.

    Introduction We investigated whether rheumatoid arthritis (RA)-related autoantibodies were associated with abnormalities on pulmonary function tests (PFTs). Methods We studied RA serostatus and PFT abnormalities within a RA registry. RA serostatus was assessed by research assays for cyclic citrullinated peptide (CCP) and rheumatoid factor (RF). Outcomes were abnormalities on clinically indicated PFTs, including restriction, obstruction, and diffusion abnormality. Logistic regression was used to obtain ORs and 95% CIs for the PFT abnormalities by RA serologic phenotypes independent of lifestyle and RA characteristics. Results Among 1272 analyzed subjects, mean age was 56.3 years (SD 14.1), 82.2% were female, and 69.5% were seropositive. There were 100 subjects with abnormal PFTs. Compared with seronegativity, seropositivity was associated with increased odds of any PFT abnormality (multivariable OR 2.29, 95% CI 1.30–4.03). When analyzing type of PFT abnormality, seropositivity was also associated with restriction, obstruction, and diffusion abnormalities; multivariable ORs were 2.48 (95% CI 1.26–4.87), 3.12 (95% CI 1.28–7.61), and 2.30 (95% CI 1.09–4.83), respectively. When analyzing by CCP and RF status, the associations were stronger for RF+ than for CCP+ (any PFT abnormality OR 1.99, 95% CI 1.21–3.27 for RF+ vs. RF−; OR 1.67, 95% CI 1.03–2.69 for CCP+ vs. CCP−) with a dose effect of higher RF titer increasing odds for each PFT abnormality (p for trend < 0.05). Conclusions Seropositive RA patients had two-fold increased risk for abnormalities on PFTs performed for clinical indications compared with seronegative RA. Patients with seropositive RA, particularly those with high-titer RF positivity, may be more likely to have obstructive and restrictive abnormalities, independent of smoking. Key points • Due to the known excess pulmonary morbidity/mortality in RA, we studied the relationship of rheumatoid arthritis (RA)-related autoantibodies with pulmonary function test (PFT) abnormalities using a large RA registry. • We evaluated whether presence and levels of cyclic citrullinated peptide (CCP) and rheumatoid factor (RF) were associated with restriction, obstruction, and diffusion abnormalities on PFTs among 1272 subjects with RA. • Seropositivity was associated with two-fold increased risk for any PFT abnormality, independent of confounders including smoking. Higher titers of RF conferred greatest risk for all PFT outcomes: obstruction, restriction, and diffusion abnormality. • These results provide evidence that patients with RA should be closely monitored for pulmonary involvement, particularly those with high-titer RF seropositivity.